Jason Kelly

Chief Executive Officer, Ginkgo Bioworks

Co-Founder and Chief Executive Officer of Ginkgo Bioworks. Ginkgo is a synthetic biology company that programmes cells for customers in the chemical, pharmaceutical, food and energy industries. The company recently raised over $730 million in venture capital to expand their automated genetic engineering foundries. It has a $100 million joint venture with Bayer to develop microbes for self-fertilizing crops, a $160 million partnership with Roche to develop antibiotics, and spinout company Motif Foodworks to make animal-free protein ingredients. It has been listed for the past three years on CNBC's Disruptor 50 List of fast-growing companies. BSc degrees in Chemical Engineering and Biology and a PhD in Biological Engineering, Massachusetts Institute of Technology (MIT).



© 2021 World Economic Forum